MNLO - The Foamix And Menlo Merger Makes Sense
Foamix (FOMX) is an Israeli biotech company that has a number of dermatological products in various stages of clinical trials and one already FDA-approved and about to launch (January 2020).
It is merging with Menlo (MNLO), which has another interesting product currently in Phase II clinical trial, Serlopitant.
Products
The company has a number of drugs in the pipeline, in different stadia of trials and approval. From the earnings deck:
The combined company will have four drugs, but only the first of these is already FDA-approved and about to experience